These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 3068049)

  • 1. [Monoamine oxidase inhibitor in the treatment of attention deficit disorder of residual type. Apropos of a case].
    Parquet PJ; Servant D; Bailly D; Meurice JP
    Encephale; 1988; 14(6):439-41. PubMed ID: 3068049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Administration of moclobemide++ in children with attention deficit hyperactivity disorder ].
    Antkowiak R; Rajewski A
    Psychiatr Pol; 1998; 32(6):751-7. PubMed ID: 10216387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADHD treatment across the life cycle.
    Spencer TJ
    J Clin Psychiatry; 2004; 65 Suppl 3():22-6. PubMed ID: 15046532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antidepressive action, pharmacokinetic characteristics and biochemical properties of cimoxatone, a new reversible MAO-A inhibitor].
    Poirier MF; Olié JP; Lôo H; Deniker P; Strolin Benedetti M; Rovei V; Lesage A
    Encephale; 1983; 9(4):331-43. PubMed ID: 6368197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial.
    Akhondzadeh S; Tavakolian R; Davari-Ashtiani R; Arabgol F; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):841-5. PubMed ID: 12921918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of attention deficit disorders in adulthood using psychostimulants and low-dose neuroleptics--a critical case report].
    Schmidt LG; Schlünder M; Reischies FM
    Psychiatr Prax; 1988 Mar; 15(2):62-5. PubMed ID: 2898788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-regulation of slow cortical potentials: a new treatment for children with attention-deficit/hyperactivity disorder.
    Strehl U; Leins U; Goth G; Klinger C; Hinterberger T; Birbaumer N
    Pediatrics; 2006 Nov; 118(5):e1530-40. PubMed ID: 17060480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs.
    Goodman WK; Charney DS
    J Clin Psychiatry; 1985 Oct; 46(10 Pt 2):6-24. PubMed ID: 3900056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety.
    Ernst M; Liebenauer LL; Jons PH; Tebeka D; Cohen RM; Zametkin AJ
    Psychopharmacol Bull; 1996; 32(3):327-34. PubMed ID: 8961775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonstimulant treatment of adult attention-deficit/hyperactivity disorder.
    Spencer T; Biederman J; Wilens T
    Psychiatr Clin North Am; 2004 Jun; 27(2):373-83. PubMed ID: 15064003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Debrisoquine and dextromethorphan phenotyping and antidepressant treatment.
    Perault MC; Bouquet S; Bertschy G; Vandel S; Chakroun R; Guibert S; Vandel B
    Therapie; 1991; 46(1):1-3. PubMed ID: 2020918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated pharmacologic treatment of attention-deficit hyperactivity disorder (ADHD).
    Horst RO; Hendren RL
    Essent Psychopharmacol; 2005; 6(5):250-61. PubMed ID: 16222910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new way to deliver psychiatric meds.
    Levin-Epstein M
    Behav Healthc; 2006 Aug; 26(8):22-3. PubMed ID: 16961036
    [No Abstract]   [Full Text] [Related]  

  • 15. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attention deficit disorder during adolescence: a review.
    Faigel HC; Sznajderman S; Tishby O; Turel M; Pinus U
    J Adolesc Health; 1995 Mar; 16(3):174-84. PubMed ID: 7779826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of comorbidity in conduct disorder with attention-deficit hyperactivity disorder (ADHD).
    Turgay A
    Essent Psychopharmacol; 2005; 6(5):277-90. PubMed ID: 16222912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sociodemographic and clinical factors associated with compliance to methylphenidate treatment in children with attention deficit hyperactivity disorder].
    Kiliç BG; Bilgiç A; Gürkan K; Aysev A
    Turk Psikiyatri Derg; 2007; 18(3):207-13. PubMed ID: 17853975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Attention deficit hyperactivity disorder, facilitating alcohol and drug abuse in an adult].
    Durst R; Rebaudengo-Rosca P
    Harefuah; 1997 May; 132(9):618-22, 680. PubMed ID: 9225572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.